Caterina Porto

发表

Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.

A. Ballabio, G. Meroni, B. Bembi, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts

G. Andria, G. Parenti, M. D. De Matteis, 2008, PathoGenetics.

NOVEL THERAPEUTIC APPROACHES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES

Caterina Porto, 2011 .

The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts

M. Barone, G. Andria, G. Parenti, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease.

A. Ballabio, G. Meroni, B. Bembi, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.

M. Sabbatini, A. Pisani, B. Visciano, 2012, Molecular genetics and metabolism.

Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease

A. Pisani, B. Visciano, G. Andria, 2012, Journal of Inherited Metabolic Disease.

N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.

M. Moracci, B. Cobucci-Ponzano, D. Priestman, 2017, Journal of medicinal chemistry.

Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.

Giorgio Colombo, Massimiliano Meli, G. Colombo, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease

M. Moracci, P. Imbimbo, D. Monti, 2021, EMBO molecular medicine.

A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.

Carmine Mollica, Anna Pichiecchio, Simona Fecarotta, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

S2.2 Enzyme replacement therapy in the infantile-onset Pompe disease

G. Andria, G. Parenti, S. Fecarotta, 2011, Acta Myologica.

The pharmacological chaperone 1‐deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha‐glucosidase

D. Lockhart, J. Flanagan, M. Cubellis, 2009, Human mutation.

Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase

M. Moracci, B. Cobucci-Ponzano, G. Peluso, 2021, Journal of enzyme inhibition and medicinal chemistry.

A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.

A. Pichiecchio, L. Morandi, G. Andria, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.

G. Colombo, M. Meli, M. Moracci, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease

A. Pisani, G. Andria, G. Parenti, 2014, Journal of Inherited Metabolic Disease.